| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.0049 | 0.9 |